melatonin has been researched along with sirolimus in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Cardell, M; Hillinger, S; Jung, FJ; Korom, S; Manz, B; Weder, W; Welp, A; Zhai, W | 1 |
| Koh, PO | 1 |
| Cho, HI; Kang, JW; Lee, SM | 1 |
| Białas, AJ; Górski, P; Makowska, J; Miłkowska-Dymanowska, J; Piotrowski, WJ; Wardzynska, A | 1 |
| Acuña-Castroviejo, D; Carriel, V; Diaz-Casado, ME; Escames, G; Fernandez-Gil, BI; Florido, J; García-López, S; Guerra-Librero, A; López, LC; Martinez-Ruiz, L; Mendivil-Perez, M; Nieto, A; Ortega-Arellano, H; Reiter, RJ; Rusanova, I; Shen, YQ; Soto-Mercado, V | 1 |
| Li, Y; Lu, HL; Ma, NF; Tao, ZS; Xu, HG; Yang, M; Zhang, RT | 1 |
1 review(s) available for melatonin and sirolimus
| Article | Year |
|---|---|
Geroprotectors as a therapeutic strategy for COPD - where are we now?
Topics: Aging; Disease Progression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Melatonin; Metformin; Oxidative Stress; Pulmonary Disease, Chronic Obstructive; Quality of Life; Sirolimus; Testosterone; Vitamin D | 2017 |
6 other study(ies) available for melatonin and sirolimus
| Article | Year |
|---|---|
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
Acute allograft rejection and immunosuppression: influence on endogenous melatonin secretion.
Topics: Animals; Cyclosporine; Graft Rejection; Heart Transplantation; Immunosuppression Therapy; Male; Melatonin; Rats; Rats, Inbred Lew; Sirolimus; Transplantation, Homologous | 2008 |
Melatonin prevents ischemic brain injury through activation of the mTOR/p70S6 kinase signaling pathway.
Topics: Analysis of Variance; Animals; Antioxidants; Cell Line, Transformed; Cell Survival; Disease Models, Animal; Functional Laterality; Gene Expression Regulation; Glutamates; Infarction, Middle Cerebral Artery; Male; Melatonin; Mice; Neurons; Neurotoxins; Rats; Rats, Sprague-Dawley; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus | 2008 |
Melatonin inhibits mTOR-dependent autophagy during liver ischemia/reperfusion.
Topics: Animals; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Calpain; Hepatocytes; Liver; Melatonin; Mice, Inbred C57BL; Oxidative Stress; Protective Agents; Reperfusion Injury; Sirolimus; Time Factors; TOR Serine-Threonine Kinases | 2014 |
Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Head and Neck Neoplasms; Humans; Melatonin; Mice; Mice, Nude; Mitophagy; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2018 |
Rapamycin could increase the effects of melatonin against age-dependent bone loss.
Topics: Animals; Bone and Bones; Bone Density; Female; Melatonin; Rats; Rats, Sprague-Dawley; Sirolimus | 2020 |